(Q51476626)

5 April 2018

title

Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. (English)

1 reference

5 April 2018

1 reference

1

1 reference

5 April 2018

Mark A Boyd

object named as

Mark Boyd

5

0 references

Kiat Ruxrungtham

12

object named as

Kiat Ruxrungtham

1 reference

5 April 2018

Jintanat Ananworanich

4

object named as

Jintanat Ananworanich

1 reference

5 April 2018

11

Praphan Phanuphak

1 reference

5 April 2018

author name string

Chris Duncombe

2

1 reference

5 April 2018

Anchalee Avihingsanon

3

1 reference

5 April 2018

Bunruan Sopa

6

1 reference

5 April 2018

B Medtech

7

1 reference

5 April 2018

Theshinee Chuenyam

8

1 reference

5 April 2018

David A Cooper

9

1 reference

5 April 2018

Joep M A Lange

10

1 reference

5 April 2018

publication date

1 March 2007

1 reference

5 April 2018

Journal of the International Association of Providers of AIDS Care

published in

1 reference

5 April 2018

volume

6

1 reference

5 April 2018

issue

1

1 reference

5 April 2018

page(s)

36-46

1 reference

5 April 2018

Metabolic disturbances and wasting in the acquired immunodeficiency syndrome

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109706295946

21 January 2018

Identifiers

DOI

10.1177/1545109706295946

1 reference

5 April 2018

release_masz2ufkvzgivoyo7etggbvhra

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/masz2ufkvzgivoyo7etggbvhra

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

5 April 2018